Eicosapentaenoic acid treatment in schizophrenia associated with symptom remission, normalisation of blood fatty acids, reduced neuronal membrane phospholipid turnover and structural brain changes

International Journal of Clinical Practice

Volumn 54, Issue 1, 2000, Pages 57-63

  Puri, B K ^a   Richardson, A J ^b   Horrobin, D F ^c   Easton, T ^b   Saeed, N ^a   Oatridge, A ^a   Hajnal, J V ^a   Bydder, G M ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^c Laxdale Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; ICOSAPENTAENOIC ACID;

ADULT; ARTICLE; BRAIN ATROPHY; CASE REPORT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ERYTHROCYTE MEMBRANE; HUMAN; IMAGE ANALYSIS; MALE; NERVE MEMBRANE; NUCLEAR MAGNETIC RESONANCE; PHOSPHOLIPID METABOLISM; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SIDE EFFECT;

ADULT; ARACHIDONIC ACIDS; BIOLOGICAL MARKERS; BRAIN DISEASES; DOCOSAHEXAENOIC ACIDS; EICOSAPENTAENOIC ACID; ERYTHROCYTE MEMBRANE; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MALE; PHOSPHOLIPIDS; SCHIZOPHRENIA;

EID: 0033980578     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Horrobin DF. Schizophrenia as a prostaglandin deficiency disease. Lancet 1977; i: 936-937.
2. Horrobin DF. The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia. Schizophr Res 1998; 30: 193-208.
3. Horrobin DF. Schizophrenia: the illness that made us human. Med Hypoth 1998; 50: 269-288.
4. Horrobin DF, Glen AIM, Vaddadi K. The membrane hypothesis of schizophrenia. Schizophr Res 1994; 13: 195-207.
5. Glen AI, Glen EM, Horrobin DF et al. A red cell membrane abnormality in a subgroup of schizophrenic patients: evidence for two diseases. Schizophr Res 1994; 12: 53-61.
6. Peet M, Laugharne JD, Mellor J, Ramchand CN. Essential fatty acid deficiency in erythrocyte membranes from chronic schizophrenic patients, and the clinical effects of dietary supplementation. Prostaglandins Leukot Essent Fatty Acids 1996; 55: 71-75.
7. 2 in schizophrenia. Biol Psychiatry 1992; 31: 214-216.
8. Gattaz WF, Schmitt A, Maras A. Increased platelet phospholipase A2 activity in schizophrenia. Schizophr Res 1995; 16: 1-6.
9. 2. Arch Gen Psychiatry 1997; 54: 487-494.
10. 2 associated with schizophrenia. Schizophr Res 1996; 21: 111-116.
11. Pettegrew JW, Keshavan MS, Panchalingam K et al. Alterations in brain high-energy phosphate and membrane phospholipid metabolism in first-episode, drug-naive schizophrenics: a pilot study of the dorsal prefrontal cortex by in vivo phosphorus 31 nuclear magnetic resonance spectroscopy. Arch Gen Psychiatry 1991; 48: 563-568.
12. Williamson P, Drost D, Stanley J et al. Localized phosphorus 31 magnetic resonance spectroscopy in chronic schizophrenic patients and normal controls. Arch Gen Psychiatry 1991; 48: 578.
13. Keshavan MS, Pettegrew JW, Panchalingam KS et al. Phosphorus 31 magnetic resonance spectroscopy detects altered brain metabolism before onset of schizophrenia. Arch Gen Psychiatry 1991; 48: 1112-1113.
14. Horrobin DF, Ally AI, Karmali RA et al. Prostaglandins and schizophrenia: further discussion of the evidence. Psychol Med 1978; 8: 43-48.
15. Horrobin DF. Schizophrenia as a membrane lipid disorder which is expressed throughout the body. Prostaglandins Leukot Essent Fatty Acids 1996; 55: 3-7.
16. Horrobin DF, Glen AIM, Cantrill RC. Clozapine: elevation of membrane unsaturated lipid levels as a new mechanism of action. Biol Psychiatry 1997; 42: 161S.
17. Mellor JE, Laugharne JDE, Peet M. Omega-3 fatty acid supplementation in schizophrenic patients. Hum Psychopharmacol 1996; 11: 39-46.
18. Peet M, Laugharne JDE, Mellor J. Double-blind trial of n-3 fatty acid supplementation in the treatment of schizophrenia. Presented at the International Congress on Schizophrenia Research, Colorado Springs, Colorado, 1997.
19. Puri BK, Richardson AJ. Sustained remission of positive and negative symptoms of schizophrenia following treatment with eicosapentaenoic acid. Arch Gen Psychiatry 1998; 55: 188-189.
20. Andreasen NC. The scale for the assessment of positive symptoms (SAPS). Iowa City: University of Iowa, 1984.
21. Andreasen NC. The scale for the assessment of negative symptoms (SANS). Iowa City: University of Iowa, 1983.
22. Coutts GA, Bryant DJ, Collins AG et al. 31P magnetic resonance spectroscopy of the normal human brain: approaches using four dimensional chemical shift imaging and phase mapping techniques. NMR Biomed 1989; 1: 190-197.
23. Richardson AJ, Cox IJ, Sargentoni J, Puri BK. Abnormal cerebral phospholipid metabolism in dyslexia indicated by phosphorus-31 magnetic resonance spectroscopy. NMR Biomed 1997; 10: 309-314.
24. Saeed N, Menon DK. A knowledge-based approach to minimize base-line roll in chemical shift imaging. Magn Reson Med 1993; 29: 591-598.
25. Moon RB, Richards JH. Determination of intracellular pH by 31P magnetic resonance. J Biol Chem 1973; 248: 7276-7278.
26. Hajnal JV, Saeed N, Soar EJ et al. A registration and interpolation procedure for subvoxel matching of serially acquired MR images. J Comput Assist Tomogr 1995; 19: 289-296.
27. Hajnal JV, Saeed N, Oatridge A et al. Detection of subtle brain changes using subvoxel registration and subtraction of serial MR images. J Comput Assist Tomogr 1995; 19: 677-691.
28. Saeed N, Puri BK, Oatridge A et al. Two methods for semi-automated quantification of changes in ventricular volume and their use in schizophrenia. Magn Reson Imaging 1998; 16: 1237-1247.
29. Saeed N, Hajnal JV, Oatridge A. Automated brain segmentation from single slice, multislice, or whole-volume MR scans using prior knowledge. J Comput Assist Tomogr 1997; 21: 192-201.
30. Dodding J. Developing brain and behaviour: the role of lipids in infant formula. London: Academic Press, 1997.
31. Finnen MJ, Lovell CR. Purification and characterisation of phospholipase A2 from human epidermis. Biochem Soc Trans 1991; 19: 91S.
32. Dawson RMC. Enzymatic pathways of phospholipid metabolism in the nervous system. In: Eichber J, Ed. Phospholipids in nervous tissue. New York: Wiley, 1985: 45-78.
33. Brock JA, Cunnane TC. Inhibition of purinergic transmission by prostaglandin E1 and E2 in the guinea pig vas deferens: an electrophysiological study. Br J Pharmacol 1996; 118: 776-782.
34. Puri BK, Hutton S, Joyce EM et al. Serial magnetic resonance imaging of the brain in first episode schizophrenia. Proc Int Soc Magn Reson Med, 4th Scientific Meeting 1996; 1: 235.
35. DeLisi LE, Sakuma M, Tew W et al. Schizophrenia as a chronic active brain process: a study of progressive brain structural change subsequent to the onset of schizophrenia. Psychiatry Res 1997; 74: 129-140.
36. Oatridge A, Saeed N, Hajnal JV et al. Ouantitation of brain and ventricular size in pregnancy and pre-eclampsia. Proc Int Soc Magn Reson Med, 7th Scientific Meeting 1999; 1: 373.
37. Vaddadi KS, Courney P, Gilleard CJ et al. A double-blind trial of essential fatty acid supplementation in patients with tardive dyskinesia. Psychiatry Res 1989; 27: 313-323.